Martin Alexander Gershon
Dr. Martin Alexander Gershon is the Managing Partner and CIO of Endeavor Life Sciences Venture Funds and Venture Studio, and well respected Senior Executive Investor -in-Residence and Lead Mentor for Techstars and a member of the Techstars NY Powered by J.P. Morgan Selection Committee.
He has been honored by Standard and Poor’s as a designated Top 100 “Healthcare Industry Leader”, recognized by Linkedin as a “Top Voice in Venture Capital and Entrepreneurship”, award winning Google Scholar in Entrepreneurship, a contributing author of healthcare entrepreneurship and venture capital at Fast Company, and has been featured on CNBC and in numerous conferences and publications as one of the leading healthcare investors, strategists, futurists and entrepreneurs.
Over the past 23 years he raised over $1B, personally founded/exited 6 startups, lead Endeavor Funds to 105 investments including Moderna and Grail, has served as Senior Strategic Healthcare Advisor for Fortune 500 Companies including McKinsey, Goldman Sachs, Bain Capital, BlackRock, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, and Novartis, and has developed Endeavor into a thriving ecosystem of partnerships with BioPharma, Digital Health, and Big Tech companies, world class CEO entrepreneurs, start-up accelerators, and prominent Ivy League universities, medical centers, and business schools like Harvard, Columbia, MIT, NYU, McGill and Johns Hopkins.
Dr. Gershon is a former Aspen Institute Business of Health Chair and Senior Fellow, Memorial Sloan-Kettering Cancer Center Mayday Fellow, Harvard and Columbia trained neuroscientist, oncologist, immunologist, FDA attorney, Lecturer and Professor at Harvard, MIT, Johns Hopkins, Oxford, Columbia Universities, and Special Advisor to the Dean and Chief Innovation and Investment Officer of Life Sciences at McGill.
Endeavor I Series B Fund
In 2009 Dr. Gershon founded Endeavor Life Science Ventures, a Series B Fund, an evergreen fund, investing in 69 groundbreaking biotech and healthcare companies like Moderna and Grail. Endeavor’s portfolio companies possess disruptive technologies, with strong scalable commercial potential, driven by great CEO entrepreneurs who look to develop partnerships within the Endeavor ecosystem to help them build their companies into the next great unicorns.
Endeavor is driven by our core principles to bring together exceptionally talented entrepreneurs, financial, strategic and operational resources, and real-life proven expertise in an ecosystem where we can do the greatest good to improve access and delivery of healthcare. We believe passionately that technology and outstanding entrepreneurs with great scientific innovations can play a role in improving health outcomes and providing a real long term pathway for all people to live a healthier life, every day.
Endeavor has created an ecosystem that creates resilient CEO/Entrepreneurs and sustainable funding for development, growth, commercialization and scalability from Seed Stage to Series B. Endeavor has designed a funnel within our ecosystem that moves our companies from the Venture Studio, to Venture Fund, and ultimately moves our companies into Corporate Accelerators and Corporate Venture who collectively have designed a clear entry and exit path of increasing investment and integration into their corporate ecosystem leading to eventual acquisition. We believe this Future Proofs our portfolio companies, building great leaders, strong teams, and companies that can withstand any crisis.
06-Dec-2023Room 1A14How will AI transform drug discovery and what challenges we need to account for?